EMEA-003360-PIP01-22 - paediatric investigation plan

tozorakimab
PIPHuman

Key facts

Active substance
tozorakimab
Therapeutic area
Infections and infestations
Decision number
P/0144/2024
PIP number
EMEA-003360-PIP01-22
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of severe viral lower respiratory tract disease
Route(s) of administration
Intravenous use
Contact for public enquiries

AstraZeneca AB 
Tel.  +44 7876398360 
E-mail: paediatrics@astrazeneca.com  

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Decision date
Compliance check done
No

Decision

Share this page